Literature DB >> 17503515

Feasibility of transcatheter intervention for severe aortic stenosis in patients >or=90 years of age: aortic valvuloplasty revisited.

Wes R Pedersen1, Paul J Klaassen, Charlene R Boisjolie, Talia A Pierce, Kevin M Harris, John R Lesser, Hidehiko Hara, Michael R Mooney, Kevin J Graham, Vibhu R Kshettry, Irvin F Goldenberg, Marc R Priztker, Robert A Van Tassel, Robert S Schwartz.   

Abstract

OBJECTIVES: The goals of this study were to determine the feasibility, safety, and early outcomes of balloon aortic valvuloplasty (BAV) for severe aortic stenosis in a nonagenarian population.
BACKGROUND: This very elderly population is expanding rapidly, has a high incidence of aortic stenosis, and uncommonly undergoes surgical aortic valve replacement. These patients may best be treated with a transcatheter approach due to comorbidities, surgical risk, and personal preference.
METHODS: We reviewed 31 consecutive patients >or=90 years of age who underwent BAV at our institution from July 2003 to August 2006 for data pertinent to patient characteristics, procedural techniques, and 30-day outcomes.
RESULTS: Our patients had a mean age of 93 +/- 3.0 years (90-101). The society of thoracic surgery risk score was 18.5 (+/-10.2) and logistic Euroscore was 35.8 (+/-19.3). Twenty-five patients (81%) underwent retrograde BAV and 6 (19%) antegrade BAV. Five patients (16%) underwent combined BAV and coronary stenting. Overall mean aortic valve area increased from 0.52 cm2 (+/-0.17) to 0.92 cm2 (+/-0.22) and mean New York Heart Association (NYHA) functional class improved from 3.4 to 1.8. Intraprocedural mortality occurred in one patient (3.2%) and 30-day mortality in three patients (9.7%).
CONCLUSIONS: BAV can be carried out in high risk nonagenarian patients with an acceptable complication rate, low perioperative mortality, and early improvement in NYHA functional class. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17503515     DOI: 10.1002/ccd.21161

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

1.  The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study.

Authors:  Brian O'Neill; Vikas Singh; Annapoorna Kini; Roxana Mehran; Evan Jacobs; David Knopf; Carlos E Alfonso; Claudia A Martinez; Pedro Martinezclark; William O'Neill; Alan W Heldman; Jennifer Yu; Usman Baber; Jason C Kovacic; George Dangas; Samin Sharma; Samantha Sartori; Mauricio G Cohen
Journal:  Catheter Cardiovasc Interv       Date:  2013-03-25       Impact factor: 2.692

2.  Time to revisit role of transcatheter balloon aortic valvuloplasty: a bridge-therapy to subsequent treatment case report.

Authors:  Akira Furuta; Hideyuki Shimizu; Takashi Hachiya; Yohei Ohno; Hiroyuki Kawajiri; Akio Kawamura; Kiyokazu Kokaji; Ryohei Yozu; Keiichi Fukuda
Journal:  Heart Vessels       Date:  2012-07-25       Impact factor: 2.037

3.  A novel clinical prediction rule for 30-day mortality following balloon aortic valuloplasty: the CRRAC the AV score.

Authors:  Sammy Elmariah; Steven A Lubitz; Amil M Shah; Marc A Miller; Dheeraj Kaplish; Sharad Kothari; Pedro R Moreno; Annapoorna S Kini; Samin K Sharma
Journal:  Catheter Cardiovasc Interv       Date:  2011-03-16       Impact factor: 2.692

4.  Balloon valvuloplasty as destination therapy in elderly with severe aortic stenosis: a cardiac catheterization study.

Authors:  Vasileios Kamperidis; Stavros Hadjimiltiades; Antonios Ziakas; Georgios Sianos; Georgios Kazinakis; George Giannakoulas; Sophia-Anastasia Mouratoglou; Athanasia Sarafidou; Ioannis Ventoulis; Georgios K Efthimiadis; Georgios Parcharidis; Haralambos Karvounis
Journal:  J Geriatr Cardiol       Date:  2015-05       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.